NCT00515554

HD18 for Advanced Stages in Hodgkins Lymphoma

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,500 (actual)
• Sponsor: University of Cologne · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to test: 1. in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles) 2. for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS.

Conditions

• Hodgkins Lymphoma

Interventions

Type	Name	Description
DRUG	Rituximab	addition of Rituximab to BEACOPP escalated
DRUG	BEACOPP escalated	chemotherapy with BEACOPP escalated

Timeline

• Start date: 2008-05-01
• Primary completion: 2019-07-01
• Completion: 2020-07-01
• First posted: 2007-08-13
• Last updated: 2020-11-13

Locations

1 site across 1 country: Germany